Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCREASE: High-Dose Icotinib in EGFR Exon 21 Mutated NSCLC
NCT02404675Phase 4Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Apr 2015
- Primary completion
- Dec 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of icotinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Status: unknown.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02404675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02404675.